Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Biomed Res Int ; 2015: 681653, 2015.
Article in English | MEDLINE | ID: mdl-26161408

ABSTRACT

This multicenter cohort study assessed the impact of molecular profiling (MP) on advanced pancreaticobiliary cancer (PBC). The study included 30 patients treated with MP-guided therapy after failing ≥ 1 therapy for advanced PBC. Treatment was considered as having benefit for the patient if the ratio between the longest progression-free survival (PFS) on MP-guided therapy and the PFS on the last therapy before MP was ≥ 1.3. The null hypothesis was that ≤ 15% of patients gain such benefit. Overall, ≥ 1 actionable (i.e., predictive of response to specific therapies) biomarker was identified/patient. Immunohistochemistry (the most commonly used method for guiding treatment decisions) identified 1-6 (median: 4) actionable biomarkers per patient. After MP, patients received 1-4 (median: 1) regimens/patient (most commonly, FOLFIRI/XELIRI). In a decision-impact analysis, of the 27 patients for whom treatment decisions before MP were available, 74.1% experienced a treatment decision change in the first line after MP. Twenty-four patients were evaluable for clinical outcome analysis; in 37.5%, the PFS ratio was ≥ 1.3. In one-sided exact binomial test versus the null hypothesis, P = 0.0015; therefore, the null hypothesis was rejected. In conclusion, our analysis demonstrated the feasibility, clinical decision impact, and potential clinical benefits of MP-guided therapy in advanced PBC.


Subject(s)
Bile Duct Neoplasms/drug therapy , Bile Duct Neoplasms/metabolism , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/metabolism , Adult , Aged , Aged, 80 and over , Bile Duct Neoplasms/pathology , Biomarkers, Tumor/metabolism , Disease-Free Survival , Female , Humans , Male , Middle Aged , Neoplasm Staging , Pancreatic Neoplasms/pathology , Retrospective Studies
2.
Cancer Res ; 73(23): 6856-64, 2013 Dec 01.
Article in English | MEDLINE | ID: mdl-24217577

ABSTRACT

Resistance to endocrine therapy occurs in virtually all patients with estrogen receptor α (ERα)-positive metastatic breast cancer, and is attributed to various mechanisms including loss of ERα expression, altered activity of coregulators, and cross-talk between the ERα and growth factor signaling pathways. To our knowledge, acquired mutations of the ERα have not been described as mediating endocrine resistance. Samples of 13 patients with metastatic breast cancer were analyzed for mutations in cancer-related genes. In five patients who developed resistance to hormonal therapy, a mutation of A to G at position 1,613 of ERα, resulting in a substitution of aspartic acid at position 538 to glycine (D538G), was identified in liver metastases. Importantly, the mutation was not detected in the primary tumors obtained prior to endocrine treatment. Structural modeling indicated that D538G substitution leads to a conformational change in the ligand-binding domain, which mimics the conformation of activated ligand-bound receptor and alters binding of tamoxifen. Indeed, experiments in breast cancer cells indicated constitutive, ligand-independent transcriptional activity of the D538G receptor, and overexpression of it enhanced proliferation and conferred resistance to tamoxifen. These data indicate a novel mechanism of acquired endocrine resistance in breast cancer. Further studies are needed to assess the frequency of D538G-ERα among patients with breast cancer and explore ways to inhibit its activity and restore endocrine sensitivity.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/genetics , Carcinoma, Ductal, Breast/genetics , Drug Resistance, Neoplasm/genetics , Estrogen Receptor alpha/genetics , Mutation, Missense , Amino Acid Substitution/physiology , Aspartic Acid/genetics , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Cell Line, Tumor , Cell Proliferation/drug effects , Female , Glycine/genetics , Humans , MCF-7 Cells , Mutation, Missense/physiology , Tamoxifen/therapeutic use
3.
Cancer ; 116(1): 251-5, 2010 Jan 01.
Article in English | MEDLINE | ID: mdl-19890960

ABSTRACT

BACKGROUND: Preoperative chemotherapy for hepatic resection of colorectal liver metastases is associated with the development of chemotherapy-associated steatohepatitis (CASH). This increases the risk of perioperative morbidity and mortality. To the authors' knowledge, an animal model for CASH has not been described previously. It has been established that fatty acid bile acid conjugates (FABACs) prevent the formation of diet-induced fatty liver. The current study was designed to establish an animal model of CASH and to use that model to study the effect of FABACs on its occurrence. METHODS: C57BL/6 mice were given different doses of oxaliplatin and irinotecan. Oxaliplatin administered once weekly at a dose of 6 mg/kg for a total dose of 24 mg/kg was tolerated best and was associated most consistently with CASH. Thus, that dose was chosen as the induction model for CASH. Subsequently, mice were divided into a control group (no treatment), an oxaliplatin group, and a CASH-prevention group, which received oxaliplatin and C20-FABAC at a dose of 150 mg/kg daily. The animals were killed after 28 days. RESULTS: Liver fat content was significantly lower (P < .0001) in the control group (51.63 mg/g) and the prevention group (62.13 mg/g) compared with the oxaliplatin group (95.35 mg/g). This difference was mainly because of the accumulation of liver triglycerides in the oxaliplatin group. CONCLUSIONS: The current results indicated that C57BL/6 mice receiving weekly oxaliplatin can be used as a model for CASH. Oral FABAC therapy reduced the development of CASH in animals that received oxaliplatin. To the authors' knowledge, this report is the first description of a model and a potential preventive treatment for CASH.


Subject(s)
Bile Acids and Salts/therapeutic use , Disease Models, Animal , Fatty Liver/chemically induced , Fatty Liver/prevention & control , Animals , Camptothecin/analogs & derivatives , Camptothecin/toxicity , Fatty Acids/therapeutic use , Irinotecan , Mice , Mice, Inbred C57BL , Organoplatinum Compounds/toxicity , Oxaliplatin
4.
Cancer ; 112(4): 731-6, 2008 Feb 15.
Article in English | MEDLINE | ID: mdl-18076012

ABSTRACT

BACKGROUND: The 21-gene recurrence score (RS) assay has been reported to accurately predict the risk of disease recurrence and chemotherapy benefit in women with estrogen receptor (ER)-positive, lymph node (LN)-negative breast cancer who are treated with tamoxifen. To the authors' knowledge, the association between the RS and clinicopathologic characteristics has been studied in randomized and case-control trials, but not in the general population. METHODS: The authors analyzed the correlation between clinicopathologic breast cancer characteristics and RS among 300 consecutive Israeli patients who were referred to undergo the test between October 2004 and October 2006. RESULTS: Low, intermediate, and high RS were noted in 109 patients (36%), 134 patients (45%), and 57 patients (19%), respectively. The median age of the patients was 54 years and the median tumor size was 1.6 cm. High tumor grade, low progesterone receptor expression, infiltrating ductal histology, and high HER-2 expression were found to be associated with a high RS, whereas patient age, tumor size, ER expression, and lymph node micrometastasis were found to correlate poorly with the RS. The ability of any of these variables, either alone or in combination, to predict the RS was limited. Similarly, neither commonly used guidelines nor the Adjuvant! Online software were found to be able to predict the RS. CONCLUSIONS: The results of the current study suggest that neither standard clinicopathologic features nor commonly used assessment tools can reliably predict the RS among referred breast cancer patients compared with a clinical trial population. These data also may indicate the need for additional studies regarding the role of the RS among certain subsets of breast cancer patients, including those with noninfiltrating ductal carcinoma histology and the presence of lymph node micrometastasis.


Subject(s)
Breast Neoplasms/pathology , Neoplasm Recurrence, Local/pathology , Aged , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Cohort Studies , Female , Gene Expression Regulation, Neoplastic , Humans , Israel , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/genetics , Prognosis , Receptor, ErbB-2/genetics , Receptors, Estrogen/genetics , Receptors, Progesterone/genetics , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors
5.
J BUON ; 12 Suppl 1: S127-36, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17935270

ABSTRACT

The addition of bevacizumab (BEV) and cetuximab to chemotherapy in the treatment of metastatic colorectal cancer (MCRC) has resulted in an increase of progression-free survival (PFS) and overall survival. BEV is usually given in the first line setting and can be combined with any chemotherapeutic regimen. BEV has activity also in the second line setting but not in the third line. It has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy. In addition, retrospective analyses demonstrate that surgery with curative intent can be performed in about 20% of the patients on BEV. Cetuximab has activity and prolongs survival in third line and above setting as observed in the NCIC study and PFS in the BOND study in patients failing irinotecan-based chemotherapy. Cetuximab increases PFS in the second line setting, as seen in the EPIC study. In the first line setting (CRYSTAL study), cetuximab increased PFS. Moreover, the percentage of patients undergoing curative resection for colorectal cancer is tripled. Skin toxicity is related to survival. In patients not having skin toxicity, dose escalation (EVEREST study) increased skin toxicity and response rate. Combination of biologicals is feasible (BOND- 2), but financial considerations constitute a problem. BEV is approved for first and second line treatments, and cetuximab is approved in patients failing irinotecan.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/drug therapy , Neovascularization, Pathologic/prevention & control , Angiogenesis Inhibitors/administration & dosage , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/economics , Bevacizumab , Cetuximab , Colorectal Neoplasms/blood supply , Colorectal Neoplasms/economics , Colorectal Neoplasms/metabolism , Colorectal Neoplasms/mortality , Disease-Free Survival , Drug Costs , Humans , Neovascularization, Pathologic/metabolism , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/metabolism , Skin Diseases/chemically induced , Treatment Outcome , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/metabolism
7.
Oncol Rep ; 12(4): 915-9, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15375522

ABSTRACT

Topoisomerase II-alpha (Topo II-alpha) is a nuclear enzyme. Its expression rises rapidly at the end of the S to G2/M phase and falls after the mitotic process ends. We have studied the immunohistochemical expression of Topo II-alpha in breast cancer and its correlation with the menopausal state, tumor type, size, lymph node metastases, stage, and estrogen and progesterone positivity. Histological sections from 50 breast cancers were immunohistochemically stained for Topo II-alpha. The percent of positive cells at the area of highest staining was recorded as Topo index. The correlation between the course of disease, survival and Topo II-alpha index was statistically significant, p<0.001. High-grade tumors showed higher Topo II-alpha levels, than those of intermediate and low-grade, p<0.01. A significant association was found between estrogen receptors positivity and Topo II-alpha, p<0.05. A higher Topo II-alpha index indicates higher probability for recurrence of the disease and overall survival. Therefore, Topo II-alpha expression has a prognostic value in breast carcinoma.


Subject(s)
Breast Neoplasms/diagnosis , Breast Neoplasms/enzymology , DNA Topoisomerases, Type II/metabolism , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm/metabolism , Biomarkers, Tumor , Carcinoma, Ductal, Breast/diagnosis , Carcinoma, Ductal, Breast/enzymology , Carcinoma, Lobular/diagnosis , Carcinoma, Lobular/enzymology , DNA-Binding Proteins , Female , Humans , Immunoenzyme Techniques , Lymphatic Metastasis/diagnosis , Menopause , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/enzymology , Neoplasm Staging , Prognosis , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Retrospective Studies , Survival Rate
8.
Dis Colon Rectum ; 47(7): 1216-24, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15148649

ABSTRACT

PURPOSE: The deleted in colorectal cancer (DCC) gene predicts a poor outcome for patients with colorectal carcinoma. This study was designed to investigate whether the expression of the DCC protein also can predict response to adjuvant chemotherapy. METHODS: The expression of DCC was evaluated immunohistochemically in 74 paraffin-embedded tumor samples from patients with Stage II (n = 41) and Stage III (n = 33) colorectal carcinomas. Follow-up time was at least 60 (median, 64) months. Follow-up was at least five years for all patients who are alive. End points of the study were recurrence of disease and death. Forty-eight patients received adjuvant therapy of 5-fluorouracil + levamisole; 28 were not treated. RESULTS: Fifty percent of tumors were deleted in colorectal cancer-positive (DCC+). Proportion of survival and disease-free survival were higher in the DCC+ patients (83 percent) than in deleted in colorectal cancer-negative (DCC-; 54 percent). In the DCC+ group, adjuvant treatment was a strong positive predictive factor for survival and disease-free survival. All DCC+ patients who received adjuvant chemotherapy (CHEMO+) are alive with no evidence of disease, whereas without chemotherapy (CHEMO-) only 54 percent are alive ( P = 0.0001). When stratification was performed by stage, patients in Stage II who were DCC+/CHEMO+ had survival and disease-free survival of 100 percent, whereas in DCC+/CHEMO- survival rate was 75 percent and disease-free survival rate 62 percent ( P = 0.042). Patients in Stage III who were DCC+/ CHEMO+ had survival and disease-free survival of 100 percent, whereas in DCC+/CHEMO- both dropped to zero ( P = 0.0002). On the other hand, in the DCC- tumors, there was no statistical significant relationship between chemotherapy and survival or disease-free survival (DCC-/CHEMO- had 57 percent survival; DCC-/CHEMO+ had 52 percent survival). CONCLUSIONS: DCC is a prognostic factor for colorectal cancer. Positive expression of DCC identifies a subgroup of patients who respond favorably to adjuvant chemotherapy, which resulted in our cases, in 100 percent survival and disease-free survival rates. Without treatment, the survival rate of DCC+ patients dropped significantly. We suggest that DCC immunostaining should be performed routinely. All DCC+ patients should receive adjuvant chemotherapy. For DCC- tumors, a larger cohort of patients should be studied before definitive conclusions can be drawn; however, clinical trials of new drug combinations should focus on DCC- patients.


Subject(s)
Carcinoma/metabolism , Cell Adhesion Molecules/biosynthesis , Colorectal Neoplasms/metabolism , Neoplasm Recurrence, Local , Tumor Suppressor Proteins/biosynthesis , Adjuvants, Immunologic/therapeutic use , Aged , Antimetabolites, Antineoplastic/therapeutic use , Carcinoma/pathology , Carcinoma/therapy , Chemotherapy, Adjuvant , Colectomy , Colorectal Neoplasms/pathology , Colorectal Neoplasms/therapy , DCC Receptor , Female , Fluorouracil/therapeutic use , Humans , Levamisole/therapeutic use , Male , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Receptors, Cell Surface , Survival Analysis , Treatment Outcome
9.
Breast Cancer Res Treat ; 80(2): 215-20, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12908825

ABSTRACT

BACKGROUND: The deleted in colorectal cancer (DCC) gene has been shown to be frequently deleted or its expression reduced or absent in glioblastomas, colorectal, gastro-intestinal, pancreatic and prostatic tumors. In the present study, we investigated the expression of DCC in surgical specimen from 75 patients with primary breast cancer. METHODS: The expression of the DCC, estrogen receptors (ER), and progesterone receptors (PR) was studied in 75 surgical specimens of primary breast cancer using an immunohistochemical method. To evaluate the outcomes of the breast cancer patients, we followed up the patients during minimum of 10 years. RESULTS: Reduced or loss of expression of DCC was identified in 45 out of 75 samples. There were significant differences between cases without metastasis or local recurrences versus these with metastasis or local recurrences (p = 0.006), and between patients alive with no evidence of malignancy versus those with recurrence or dead of disease (p = 0.005). There were no significant differences between the DCC status and age, sex, tumor location, stage, grade, or proportion of patients who received adjuvant therapy. CONCLUSIONS: These findings suggest that a decrease in DCC expression may influence the prognosis of breast carcinoma patients.


Subject(s)
Breast Neoplasms/metabolism , Breast/metabolism , Cell Adhesion Molecules/metabolism , Tumor Suppressor Proteins/metabolism , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/surgery , DCC Receptor , Female , Humans , Immunohistochemistry , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Neoplasm Staging , Receptors, Cell Surface , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...